clinicaltrialsarena.com
Eli Lilly reports positive data from trial of Omvoh for Crohn's disease
Long-term maintenance of clinical and endoscopic remission is a key goal in Crohn’s disease care. Positive two-year data and FDA approval may affect treatment options for adults, including people who previously failed other biologics.
Adults with moderately to severely active Crohn's disease, especially those considering or using biologic therapies; gastroenterologists and IBD clinicians; clinical researchers and people tracking new IBD drug approvals.
What To Know
Eli Lilly reported positive long-term outcomes from the Phase III open-label extension VIVID-2 trial of Omvoh (mirikizumab-mrkz) in adults with moderately to severely active Crohn's disease. The article summarizes maintenance of clinical remission (CDAI) and endoscopic response/remission rates at two years and notes a consistent long-term safety profile.
It also mentions FDA approval for adults and ongoing additional studies (paediatric, UC, Phase IV real-world evidence). These results describe two-year outcomes from participants who continued mirikizumab after initial response in the VIVID-1/VIVID-2 program.
Large proportions reportedly maintained clinical remission and endoscopic response at two years; some participants who were not in remission at one year improved during the second year. The piece highlights the drug’s mechanism (IL-23p19 targeting) and notes the therapy’s recent FDA approval for adults with moderately to severely active Crohn’s disease.
Practical points: this is a news report summarizing trial results and regulatory status rather than a full peer-reviewed publication. It does not provide detailed study methods, subgroup analyses, or individual risk information.
This article is a media summary of company-reported trial results (Phase III VIVID program) and mentions FDA approval. It is not a full scientific paper—details on study design, statistical analyses, or long-term safety specifics are not provided here. For treatment decisions, consult detailed trial publications and your clinician.
